Trial of PBF-509 and PDR001 in Patients With Advanced Non-small Cell Lung Cancer (NSCLC)

NCT02403193 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

92

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-small Cell Lung Cancer (NSCLC)

Interventions

DRUG: PBF-509_80 mg
DRUG: PBF-509_160 mg
DRUG: PBF-509_320 mg
DRUG: PBF-509_640 mg
DRUG: Combo PBF-509 (160 mg) + PDR001
DRUG: Combo PBF-509 (320 mg) + PDR001
DRUG: Combo PBF-509 (640 mg) + PDR001
DRUG: RP2D (PBF-509+PDR001)_immuno naïve
DRUG: Experimental: RP2D (PBF-509+PDR001)_immuno treated

Sponsor

Palobiofarma SL

Collaborators

[object Object]
[object Object]